Search Immortality Topics:

Page 20«..10..19202122..3040..»


Aspect Biosystems Announces US $20 Million Series A Financing to Advance Its Leading Platform for 3D Bioprinting of Human Tissue – Business Wire

Posted: January 14, 2020 at 2:44 pm

VANCOUVER, British Columbia--(BUSINESS WIRE)--Aspect Biosystems (Aspect) (the Company), a biotechnology company pioneering microfluidic 3D bioprinting of human tissues, today announced a US $20 million Series A financing round. Radical Ventures, a venture capital firm investing in entrepreneurs developing and applying deep tech to solve global problems and transform massive industries, led the round with participation from existing and new investors, including Pangaea Ventures, Pallasite Ventures, and Rhino Ventures. Aspect will use this capital to advance multiple tissue therapeutic programs, expand its technology platform capabilities, and grow its world-leading team.

Aspects broadly applicable technology platform enables the creation of living human tissues with unprecedented control, flexibility, and precision. In addition to Aspects internal tissue therapeutic programs for regenerative medicine, the Company works with its global partners to create high-value solutions that will transform medical research and clinical practice.

We are thrilled to close this important institutional financing round with a group of world-class investors who believe in our bold vision, said Tamer Mohamed, CEO, Aspect Biosystems. This funding speaks to the power of our technology and strategy in addressing multiple applications in therapeutic discovery and regenerative medicine, and will allow us to accelerate internal innovation and expand our global partnerships. With our technology platform, interdisciplinary team of scientists and engineers, and leading collaborators, we are developing a new wave of solutions that have the potential to transform how we heal injury and disease.

We are very excited to partner with the excellent Aspect team to support the growth of their world-leading 3D bioprinting platform and the development of breakthrough technologies aimed at radically transforming human health, said Jordan Jacobs, managing partner, Radical Ventures.

About Aspect Biosystems

Aspect Biosystems is a privately held biotechnology platform company pioneering the microfluidic 3D bioprinting of human tissues. The Companys proprietary technology has the potential to shape every aspect of human health by enabling the creation of human tissues for medical research, therapeutic discovery, and regenerative medicine. Aspect is focused on partnering with academic institutions and biopharma companies to facilitate high-value discovery and development. The Company is also advancing internal tissue therapeutic programs for regenerative medicine, with an initial focus on metabolic diseases and musculoskeletal injuries and disorders. Learn more at http://www.aspectbiosystems.com.

About Radical Ventures

Radical Ventures is a venture capital firm investing in bold entrepreneurs developing and applying artificial intelligence and other deep technologies to invent the future. Based in Toronto, Radical Ventures launched a US $350 Million fund in 2019 focused on Series A investments. Radical Ventures was created by the founders of leading artificial intelligence company Layer 6 (acquired by TD Bank Group), who also co-founded the Vector Institute for Artificial Intelligence. Learn more at http://www.radical.vc.

The rest is here:
Aspect Biosystems Announces US $20 Million Series A Financing to Advance Its Leading Platform for 3D Bioprinting of Human Tissue - Business Wire

Recommendation and review posted by G. Smith

Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area | DNA RNA and…

Posted: January 14, 2020 at 2:44 pm

DetailsCategory: DNA RNA and CellsPublished on Monday, 13 January 2020 16:23Hits: 275

mRNA-6231 encodes a long-acting selective IL-2 to preferentially expand regulatory T cells that suppress immune activity in autoimmune diseases

mRNA-6981 encodes PD-L1 to treat autoimmune disease, initially to be developed in autoimmune hepatitis

Company to expand pipeline of innovative vaccines in the near term based on clinical success of infectious disease vaccine portfolio to date

CAMBRIDGE, MA, USA I January 12, 2020 I Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it has entered a new autoimmune therapeutic area. Building on the clinical validation of systemic delivery of mRNA provided by data from its antibody against the chikungunya virus (mRNA-1944) program, this new therapeutic area will include autoimmune and inflammatory diseases. The Company also announced that it will expand its pipeline of innovative vaccines in the near term, following six positive Phase 1 clinical trial readouts from its infectious disease portfolio and the initiation of a Phase 2 study for its CMV vaccine (mRNA-1647).

Modernas pipeline is organized into six modalities based on similar mRNA technologies, delivery technologies and manufacturing processes. The Companys approach is to leverage early programs within a modality to generate clinical data and insights that reduce the technology risk of subsequent programs and accelerate the expansion of the pipeline in that modality. Todays announcement reflects the Companys belief that recent positive Phase 1 data from its infectious disease vaccine portfolio, including its complex CMV vaccine, and chikungunya antibody program have de-risked its prophylactic vaccines and systemic therapeutics modalities. As a result, Moderna intends to bring new development candidates forward within these two areas.

2019 was an inflection point for Moderna with significant clinical advances resulting from our investments in science and manufacturing capabilities. The positive Phase 1 results from our CMV vaccine and chikungunya antibody programs validate our approach and help clinically de-risk the delivery technologies for our prophylactic vaccines and systemic therapeutics modalities. Based on these learnings, we are excited to enter a new therapeutic area in autoimmune disease and announce two new development candidates, said Stphane Bancel, Modernas chief executive officer. We are entering 2020 with clear priorities, a strong cash balance and a talented team of employees focused on achieving our mission. With our CMV vaccine, we are preparing for our first pivotal Phase 3 study and we look forward to announcing additional new development candidates in our two clinically de-risked modalities, prophylactic vaccines and systemic therapeutics.

Mr. Bancel will present an update on the Company and its pipeline of mRNA development programs on Monday, January 13, 2020 at 4:30 p.m. PT at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will be followed by a question and answer session. A live webcast of both the presentation and question and answer session will be available under Events & Presentations in the investors section of Modernas website at investors.modernatx.com. A replay of the webcast will be archived on Modernas website for 30 days following the presentation.

Moderna currently has 21 mRNA development candidates in its portfolio with 13 in clinical studies. Across Modernas pipeline, more than 1,500 participants have been enrolled in clinical studies. The Companys updated pipeline can be found at http://www.modernatx.com/pipeline.

About Modernas New Autoimmune Therapeutic Area

Autoimmune diseases are characterized by immune activation in response to antigens normally present in the body, reflecting a loss of tolerance. Within this therapeutic area, the Company is developing two potential medicines, mRNA-6231 and mRNA-6981, designed to engage peripheral tolerance pathways to dampen autoimmune activation and help restore immune homeostasis, thereby reducing autoimmune pathology.

mRNA-6231 is an mRNA encoding for a long-acting IL-2 mutein designed to preferentially activate and expand the regulatory T cell population, dampening the immune response.

mRNA-6981 is an mRNA encoding for PD-L1 and is designed to augment cell surface levels of PD-L1 on myeloid cells, providing co-inhibitory signals to self-reactive lymphocytes.

As an initial step to addressing a range of autoimmune indications, the Company plans to conduct a Phase 1 study of mRNA-6231 in healthy adult volunteers and intends to pursue proof-of-concept with mRNA-6981 in a Phase 1 study in type 1 autoimmune hepatitis (AIH), a condition that involves liver inflammation and can lead to cirrhosis and liver failure. The Phase 1 study of mRNA-6231 will be the first clinical demonstration of subcutaneous administration of this delivery technology.

Both of these new autoimmune development candidates share the same delivery technology as mRNA-1944, the antibody against chikungunya, reducing technology risk. The autoimmune therapeutic area is Modernas fifth therapeutic area, in addition to infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases.

Program Updates by Modality:

Prophylactic vaccines: Moderna is developing vaccines against viral diseases where there is unmet medical need including complex vaccines with multiple antigens for common diseases, as well as vaccines against threats to global public health.

Serious infections transmitted from mother to baby

Serious respiratory infections

Global public health programs

Cancer Vaccines: These programs focus on stimulating a patients immune system with antigens derived from tumor-specific mutations to enable the immune system to elicit a more effective anti-tumor response.

Intratumoral Immuno-Oncology: These programs aim to drive anti-cancer T cell responses by injecting mRNA therapies directly into tumors.

Localized Regenerative Therapeutics: Localized production of proteins has the potential to be used as a regenerative medicine for damaged tissues.

Systemic Secreted & Cell Surface Therapeutics: In this modality, mRNA is delivered systemically to create proteins that are either secreted or expressed on the cell surface.

Systemic Intracellular Therapeutics: These programs aim to deliver mRNA into cells within target organs as a therapeutic approach for diseases caused by a missing or defective protein.

Information about each development candidate in Modernas pipeline, including those discussed in this press release, can be found on the investor relations page of its website: https://investors.modernatx.com/.

Corporate Objectives

Moderna continues to execute on its corporate objectives for 2019-2020, which include:

Corporate Updates

Key 2020 Investor and Analyst Event Dates

About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the bodys cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Modernas platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca, Plc. (NASDAQ: AZN) and Merck, Inc. (NASDAQ: MRK), as well as the Defense Advanced Research Projects Agency (NASDAQ: DARPA), an agency of the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been named a top biopharmaceutical employer by Science for the past five years. To learn more, visit http://www.modernatx.com.

1Biomedical Advanced Research and Development Authority (BARDA), Defense Advanced Research Projects Agency (DARPA) and The Bill and Melinda Gates Foundation (BMGF). Additional funding is subject to agreement on scope of additional projects.

SOURCE: Moderna Therapeutics

See the original post here:
Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area | DNA RNA and...

Recommendation and review posted by G. Smith

Antibe Therapeutics Expands Executive Team in Preparation for Large Market Partnering – Financial Post

Posted: January 14, 2020 at 2:44 pm

TORONTO Antibe Therapeutics Inc. (Antibe or the Company) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce the hiring of Dr. Rami Batal in the new role of Senior VP, Commercial Strategy. The creation of this position represents a further step in the Companys partnering efforts for its lead drug, ATB-346, and for our overall drug platform.

Ramis role will be to leverage the Companys recent commercial strategy initiatives, including the now-completed health economics study, and the on-going comprehensive market opportunity assessment and payor study. A key aspect of his role involves providing partners with a robust commercial strategy package, including an in-depth framework on positioning, launch-planning and reimbursement.

Dan Legault, Antibes CEO, remarked, This new role will help us maximize the value of ATB-346 as we ramp up partnering discussions for the larger markets. Ramis deep experience in commercialization of analgesics will enable us to fully capture and communicate the drugs commercial potential to our partners. We are delighted to welcome him to our growing team.

Ramis career has centred on pharmaceutical development and commercialization of pain and central nervous system drugs worldwide. A business development leader with strong scientific credentials and frontline healthcare expertise, he has also guided in-licensing on behalf of several large pharma companies, gaining first-hand knowledge of their decision-making and licensing practices. Rami earned his PhD in Experimental Medicine at McGill University, and his MBA in Finance at Concordia University. He is also a licensed pharmacist.

The Company also announced that Scott Curtis has been promoted to the newly created position of Executive VP to coordinate corporate activities as business development activities accelerate.

About Antibe Therapeutics Inc. Antibe develops safer, non-addictive medicines for pain and inflammation. Antibes technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce an improved and patented medicine. Antibes lead drug, ATB-346, targets the global need for a safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibes pipeline, targets the urgent global need for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. Citagenix Inc., an Antibe subsidiary, is a market leader and worldwide distributor of regenerative medicine products for the dental marketplace. http://www.antibethera.com.

Forward Looking Information This news release includes certain forward-looking statements, which may include, but are not limited to, the proposed licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions will, anticipate, believe, plan, estimate, expect, intend, propose and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Companys inability to secure additional financing and licensing arrangements on reasonable terms, or at all, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200113005264/en/

Contacts

Antibe Therapeutics Inc. Dan Legault Chief Executive Officer (416) 473 4095 dan.legault@antibethera.com

See the original post:
Antibe Therapeutics Expands Executive Team in Preparation for Large Market Partnering - Financial Post

Recommendation and review posted by G. Smith

Analysis on Japan’s Biosimilars Landscape, 2020 – In the Next 7 Years, Biosimilars Will Pose a ~$550B Opportunity in Japan, Due to the Patent Expiry…

Posted: January 14, 2020 at 2:44 pm

Dublin, Jan. 14, 2020 (GLOBE NEWSWIRE) -- The "Japanese Biosimilars Landscape Study, 2009-2020" report has been added to ResearchAndMarkets.com's offering.

In this report, we attempt to analyze trend/requirement of regulatory approval of biosimilars based on Ex-Japan clinical trialdata, factors responsible for each key launched biosimilar penetration (Made in Japan vs. Tested by Japan), and the future competitive landscape in the biosimilars space in Japan.

We also attempt to analyze detail BS market of EPO, Filgrastim/Pegfilgrastim/Insulin/Lantus apart from other key complex Mab Biosimilar opportunities and list out niche opportunities in biosimilar space in Japan. Details of all major consolidation activities done by JP/Foreign companies in biosimilar space in the last five years and crisp summary on strategies of each key player (~21 JP local companies, multinational companies), their interest & focus for future collaboration in biosimilar space.

Since 2009, 25 biosimilars of 12 originator products are approved in Japan and have yielded mixed performances and attained annual sales of ~32.4b ($300m).

Unique biosimilars landscape with the entry of NESP biosame by originator Kyowa Hakko Kirin through its subsidiary, co-promotion/marketing collaboration with local companies for the front-end skill sets (Ayumi, Kyowa Hakko Kirin, Teijin) and few skipped listing to better manage constant supply (Pfizer), a key requirement by MHLW, makes Japan a distinct market vs. US and EU.

Less stringent regulatory environment vs. US for approval, increasing healthcare burden and strong foothold of the marketers have played key roles in this early uptake which is at par to one of the best generic small molecule penetration in Japan in a short time (Filgrastim BS-volume share~45% in two years, Lantus BS- ~9% in 2 months vs. Lipitor generics ~50% volume share).

While analyzing the launched biosimilar penetration since 2009 in Japan, bolstering uptake of Enbrel, Rituxan, and Lantus biosimilar vs. very slow uptake of Remicade BS mainly been attributed with the use of biosimilars in DPC hospitals,product reimbursement under high cost medical care benefit system and front end presence of the local partner.

Despite the string of recent biosimilars approvals, healthcare professionals still harbor concerns over the quality of biosimilars.

MHLW's announcement to update a decade back biosimilars guideline by FY2020 to reduce cost of development as well as to increase confidence of physician on quality, is indicative of biosimilar as important weapon for Chuikyo(Central social Insurance Medical Council) to curb healthcare cost. Further, Biosame pricing game will play a major role in the future for biosimilar penetration. We see that Abenomics measures and government involvement in biosimilars use would lead to the Biosimilars promotions in the coming times in Japan.

Mixed strategies by originator for Bio-same launch (Kyowa Hakko Kirin to launch Biosame vs. Chugai said not to launch Biosame), therapy area wise biosimilars cherry picking by mid-size Japanese companies, and different strategies by local generic companies (NichiIko heading for global market vs. Sawai testing through co-promotion and Towa yet not decided to enter), demonstrates each company's different need and approach to cater biosimilar opportunities in Japan.

Since the last five years, most of the companies have some alliance in place for biosimilars, with most of the Japanese companies undertaking pacts with South Korean companies to ride on their back of biosimilar mAb expertise.

There is a trend of doing product specific alliance by most of the JP companies active in BS space and to go step by step on this high risk/high return opportunities. Against this backdrop, multinational companies like Pfizer are setting their sights on this market without local partnership taking advantage of pro-biosimilar environment to capture decent biosimilar market share. Overall, in the Japan market, each opportunity has a different competitive landscape for itself, and some companies are looking for niche opportunities in biosimilar space as per their specialty therapy area- like ophthalmology BS (Lucentis), Enzyme therapy BS (JCR).

While launched biosimilars now generates ~32b ($300m) sales and its penetration is accelerating, MHLW's approval of Biosame of NESP based on same clinical data as the originator NESP, and current ongoing dialogs to price Biosame higher than biosimilars, indicative of Biosame to be the key hurdle in the future for mid-size biosimilar companies in Japan. In the year 2020, MHLW's stand on Biosame, will be important to decide future of theses mid-size /generic biosimilar developers. Around ~550b opportunity is opening for biosimilar in the next 7 years in Japan due to patent expiry of Wave 2-3 biologics.

Story continues

Key Topics Covered

CHAPTER 1: EXECUTIVE SUMMARY

CHAPTER 2: JAPANESE GOVERNMENT AND CHUIKYO INITIATIVES TO INCREASE BIOSIMILAR PENETRATION IN JAPAN

CHAPTER 3: LESSONS FROM LAUNCHED BIOGENERIC PROGRESS IN JAPAN SINCE 2009

CHAPTER 4: GROWTH HORMONE MARKET (SOMATROPIN) IN JAPAN

CHAPTER 5: ANEMIA MARKET IN JAPAN

CHAPTER 6: FILGRASTIM (GRAN) BS

CHAPTER 7: REMICADE (INFLIXIMAB) BS

CHAPTER 8: LANTUS (INSULIN GLARGINE) BIOSIMILAR

CHAPTER 9: ENBREL (ETANERCEPT) BIOSIMILAR

CHAPTER 10: ONCOLOGY BIOSMILARS ERA STARTS WITH RITUXAN (RITUXIMAB) BIOSIMILAR

CHAPTER 11: HERCEPTIN (TRASTUZUMAB) BIOSIMILAR

CHAPTER 12: AVASTIN (BEVACIZUMAB) BIOSIMILAR

CHAPTER 13: FABRAZYME (AGALSIDASE BETA) BIOSIMILAR

CHAPTER 14: FORTEO (TERIPARATIDE) BIOSIMILAR

CHAPTER 15: NEXT WAVEOF BIOSIMILAR OPPORTUNITIES IN JAPAN

CHAPTER 16: BIOSIMILAR/BIOPHARMA CMO OPPORTUNITY

CHAPTER 17: REGULATORY APPROVAL REQUIREMENT FOR COMPLEX MAB BIOSIMILAR IN JAPAN

CHAPTER 18: LICENSING/CONSOLIDATION ACTIVITIES IN BIOSIMILAR SPACE IN JAPAN

CHAPTER 19: JAPANESE COMPANIES ACTIVE INTO BIOGENERICS SPACE

For more information about this report visit https://www.researchandmarkets.com/r/edigvv

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Originally posted here:
Analysis on Japan's Biosimilars Landscape, 2020 - In the Next 7 Years, Biosimilars Will Pose a ~$550B Opportunity in Japan, Due to the Patent Expiry...

Recommendation and review posted by G. Smith

NutriDrip, ahead of funding round, sets up aging and hangover treatments at Wynn Hotels, Equinox – CNBC

Posted: January 14, 2020 at 2:43 pm

At Clean Market in Midtown, New Yorkers have a wide menu of healthy offerings to choose from, such as "superfood smoothies" and bowls with a side of a "moon dust of choice."

But if clean food isn't enough, customers can also get a boost from vitamins delivered intravenously at the NutriDrip bar. The service is growing in popularity and attracting customers from fitness and lifestyle companies like Equinox to some major hotel chains.

NutriDrip sells 15 vitamin infusions administered by medical professionals via an IV drip that takes about 30 minutes. The Nutribody drip aims to support fat loss with a combination of l-carnitine, taurine, vitamin C, B complex, among others. There are also the popular hangover remedies Basic Recover, Super Recovery and Mega Recovery which range in price from $119 to $199 depending on how much you're hurting from the night before. The Nutriyouth drip claims the ability to "help stop cellular aging in its tracks" with a mixture of anti-aging enzymes, molecules and vitamins for $599.

Founded five years ago, NutriDrip is looking to expand in 2020 with a Series A funding round in the first half of this year. Executives declined to say how much money they're looking to raise.

"Over the last three years, IV nutrient therapy, specifically NutriDrip, has grown, at like a 60 to 80% year-over-year growth rate, even while opening new stores," said co-founder Asa Kitfield. "So we're really excited to see what sort of saturation the market can see on like a local and national basis."

One of its new corporate clients is Wynn Hotel will be offering NutriDrip IV drips to its guests in Las Vegas in early 2020.

A woman receives a vitamin infusion via intravenous drip.

Carlos Allegri | Reuters

"As many of our guests now expect a more holistic set of wellness options, we have evolved to include broader wellness themes related to functional wellness, physical fitness, and healthy cuisine," said a Wynn spokeswoman, adding "providing IV therapy is one more way to help our guests maintain personal wellness routines while they are traveling."

The Equinox Hotel in Hudson Yards also has been offering the service to guests when it opened last summer. Kitfield also told CNBC, NutriDrip is slowly rolling out the service to other Equinox gym locations in early 2020 as well.

Equinox executives Jeffrey Weinhaus and Harvey Spevak were early investors in NutriDrip parent company Clean Market, along with real estate investor Jack Terzi, Seritage Growth Properties CEO Ben Schall, fashion designer Andrew Rosen and venture capital firm Able Partners.

Celebrities, including Madonna, Rihanna and Simon Cowell, are reportedly fans of IV vitamin treatments, but it's drawn some controversy.

"Anytime you poke a hole in somebody's vein, there is some risk that they'll bleed excessively. There's also some risk that they will clot excessively," said Dr. David Katz, founding director of Yale University's Prevention Research Center. "So the risks are not great. And the risks are not very common, but there are risks, and the only way to justify any risk in medicine is by a greater likely benefit."

He said there is "minimal evidence that there is any meaningful benefit for most people."

Kitfield said NutriDrip doesn't make grand promises about its treatments but said the company and customers clearly believe in its benefits.

"When you look at our business where 50 to 60% of our revenue comes from regulars, and that's why we continue to grow, the proof is kind of in the pudding, Kitfield said.

According to the Global Wellness Institute, a nonprofit that tracks the industry, the global wellness market is a $4.5 trillion industry. While IV therapy and alternative medicine is a small portion of the overall spending, GWI says it's among the fastest-growing sectors.

Read more:
NutriDrip, ahead of funding round, sets up aging and hangover treatments at Wynn Hotels, Equinox - CNBC

Recommendation and review posted by G. Smith

Free Health Seminar: IMPROVE YOUR COMPETITIVE EDGE: MOBILITY & STAMINA IN FITNESS AND SEXUAL HEALTH – Villages-News

Posted: January 14, 2020 at 2:43 pm

2nd in the 2020 3-part wellness series, and one of Dr. Millers most sought after speaking topics. Learn ways to increase strength, mobility, balance, stamina, and muscle recovery after exercise, AND hear information that can significantly improve sexual health as you age.*Come early for best seats, doors open at 2:30pm.

Free health & wellness seminar by international speaker and PBS health series featured expert, Board Certified Anti-Aging & Functional Medicine physician, Dr. Kristin Miller, MD, FAARM, FAAMFM. Event co-hosted by Tim Taylor, President of Care Beyond.

Dr. Miller has been a practicing physician, owner, & medical director of multiple medical practices with a focus on holistic, patient-centered, evidence-based medicine combining principles of Western and Eastern medicine. She has been medical director of Medi-Spas establishing protocols and focusing on advanced techniques of skin rejuvenation and BoTox & filler injection treatments. Dr. Millers integrative approach includes state-of-the-art laboratory testing methods and development of customized treatments, including nutritional and lifestyle modifications, pharmaceutical grade nutrients and herbs, and collaboration in the development of new compounded neutraceuticals. The goal for treatment is to assist the bodys natural pathways to return to a more healthy, balanced state for optimal health at any age.

Dr. Miller has written extensively in patient-focused health journals. She has published peer-reviewed articles and has spoken at many medical meetings and seminars throughout the United States and abroad. She has been featured in the media and is internationally known as an expert in the field of Anti-Aging, Metabolic and Functional Medicine.

Dr. Millers focus is now to reach beyond the clinic doors, to share innovative evidenced-based information about health and wellness so you can make the best choices for YOU. She currently works with a non-profit foundation in California whose focus is wellness education and giving back to the community, providing financial assistance for healthcare to those in need.SAVE THE DATE: MARCH 1st: Part 3 of the 3-part series: UNLOCK YOUR MEMORY POTENTIAL

View original post here:
Free Health Seminar: IMPROVE YOUR COMPETITIVE EDGE: MOBILITY & STAMINA IN FITNESS AND SEXUAL HEALTH - Villages-News

Recommendation and review posted by G. Smith


Page 20«..10..19202122..3040..»